New Drug Delivery System Developed for Chemo-Induced Hearing Loss
The novel drug delivery system uses hydrogels and nanoparticles to protect against hearing loss caused by the chemotherapy drug cisplatin.
Tag: cisplatin
All
Latest
All
Latest
WSU Researchers to Build Ototoxic Drug Database
Two Washington State University (WSU) researchers want to help pharmaceutical companies know if their drugs may cause hearing loss before they hit the market, according to an article on the WSU website.
All
Latest
IU Cancer Center Researcher Awarded $5.7 Million Grant to Study Chemo-Induced Hearing Loss
Nearly 6 million patients globally are diagnosed with a cancer each year in which first-line therapy potentially includes highly toxic, platinum-based chemotherapies. While the treatment may lead to hearing loss, ringing in the ears, numbness in hands and feet, and other side effects, it is the only proven cure for the vast majority of testicular cancer patients.
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Otonomy Announces Upcoming Presentations at 42nd ARO MidWinter Meeting
“Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss, and otoprotection,” said Kathie Bishop, PhD, chief scientific officer of Otonomy.
Read More
University of Connecticut Researchers Find Protein Connected with Hearing Loss
UConn otolaryngologist Kourosh Parham and his colleagues report in “Hearing Research” that levels of prestin, a protein found only in cells in the inner ear, rise sharply when those cells are damaged and start to die.
Read More
Sensorion Presents SENS-401 Data at Ci2018 Conference
Data from the presented studies showed that SENS-401 protected inner ear function and enhanced sensory hair cell survival in preclinical models of acoustic trauma and, separately, cisplatin infusion.
Read More
Sodium Thiosulfate May Help Reduce Cisplatin-Related Hearing Loss, New Study Says
The study showed that STS administered six hours after Cisplatin could reduce the severity of hearing loss without affecting the chance of cure for the cancer.
Read More
Acousia Therapeutics Receives $11.8 Million Funding for Hearing Loss Drug Research
The company’s most advanced drug candidate ACOU085 is being developed for clinical application in otoprotection (cisplatin-related) and will be profiled in functional improvement of hair cells.
Read More
Fennec Pharmaceuticals’ Cisplatin-Ototoxicity Treatment Given Breakthrough Therapy Designation
According to the FDA, Breakthrough Therapy designation is given when preliminary clinical evidence has been provided to show that a treatment effect may represent substantial improvement over available therapies for the treatment of a serious condition.
Read More
Sensorion Presents SENS-401 Data at ARO 2018 MidWinter Meeting
SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments.
Read More
NIH Researchers Find Link Between Cisplatin Build-up and Hearing Loss
Using a highly sensitive technique to measure and map cisplatin in mouse and human inner ear tissues, researchers found that forms of cisplatin build up in the inner ear.
Read More
Otomagnetics Reduces Cisplatin-Related Hearing Loss in Mice, New Study Shows
Using a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%.
Read More
Sensorion Receives Orphan Drug Designation for Chemotherapy-Induced, Hearing Loss Treatment
The drug is a therapy in development for the treatment of hearing disorders, for the prevention of Platinum-Induced Ototoxicity in pediatric patients.
Read More
Otonomy Enrolls Patients for Phase 2 Trial of OTO-104 for Prevention of Hearing Loss During Chemotherapy
Otonomy has announced the enrollment of the first patients in a Phase 2 clinical trial evaluating OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.
Read More
Hearing Loss Can Result from Cisplatin Therapy for Cancer
Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University, who found that increased doses of cisplatin were associated with increased hearing loss.
Read More
Inherited Genes Factor Into Hearing Loss Among Cancer Patients
St. Jude Children’s Research Hospital scientists have found that variations of inherited genes are associated with hearing loss in young cancer patients treated with cisplatin, a drug widely used to treat brain tumors and other types of cancer.
Read More
Kathleen Campbell Updates ADA Attendees on Otoprotective Agents That Are Currently in or Approaching Clinical Trials
In the General Session of the 2014 Academy of Doctors of Audiology (ADA) Convention held November 6-9, 2014 in Las Vegas, Kathleen Campbell, PhD, of Southern Illinois University School of Medicine, gave an interesting and lively talk on ototoxicity and the role of pharmaceutical agents in hearing loss management and prevention.
Read More